The Platform and the Void
On how lived experience becomes visible — and what it takes to count as evidence.
After a while, it begins to feel that the difficulty is not in what is being said, but in how it is allowed to appear. The stories are there — repeated, consistent, often precise. What remains uncertain is not their content, but their passage: how they move, or fail to move, from experience into something that can be recognized, compared, and retained. Before any argument takes hold, something quieter has already decided what can count.
There is, in almost every contemporary public dispute, a recurring detail: before you can win the argument, you must win the form. Before reason, the field; before proof, the device that determines what can count as proof.
Who speaks.
In what format.
By which method.
With what vocabulary.
By what criteria of validity.
Contemporary politics and health policy, perhaps more than any other domain, rarely exclude voices through outright censorship. It excludes them through the design of the room, the syntax of the protocol, and the quiet liturgy of procedures.
Some experiences make it into spreadsheets, systematic reviews, and technical reports. Others remain outside, reduced to testimony, to noise, to isolated cases, to affect without status. They are not so much refuted as managed downward — demoted in category.
It is from this fissure that THR Global emerges.
Conceived by Kurt Yeo — co-founder of Vaping Saved My Life, a South African consumer group that advocates for tobacco harm reduction and vaping-related education, and a longtime smoker who claims to have quit through flavored vapes — the platform condenses a drama larger than himself: the attempt to make a private experience pass through the customs of evidence and enter, with some degree of legitimacy, the space where policy takes shape and circulates as official language.
At first glance, the initiative may seem like just another advocacy site in an already saturated ecosystem of campaigns, manifestos, reports, and testimonials on vaping, nicotine, and smoking cessation. Look closer, however, and its ambition runs deeper.
THR Global does not simply aim to publish stories; it seeks to recalibrate the regime of value in which those stories circulate. It seeks to transform what, for years, has been treated as a dispersed, subjective, and politically minor experience into something closer to a legible body of social evidence.
In simple terms, the platform seeks to address a problem that advocates of tobacco harm reduction have long recognized: despite possessing thousands — perhaps millions — of stories, the movement still lacks proportional weight in the arenas where policy takes shape, acquires normative force, and is enforced.
This is THR Global’s central point: not merely to give visibility to consumers, but to give institutional form to that visibility.
What begins to take form
Public discourse about digital platforms tends to exaggerate their novelty, as if each interface inaugurated a world. In the case of THR Global, however, what matters is not the technology but what it seeks to discipline: the shape of experience. This is not about technical innovation, but methodological ambition.
The platform rests on a simple — and deeply political — premise: personal accounts from former smokers who switched to lower-risk alternatives have been systematically underestimated, not only because of what they say but because of how they appear: fragmented, discontinuous, confined to the least-valued format of public debate: the isolated testimony.
The proposed response is standardization.
Each submission follows a structured format: smoking history, prior quit attempts, product used, and perceived outcomes. A seemingly neutral gesture, simple, almost administrative. But this is where the operation begins.
Instead of scattered narratives, a series.
Instead of the irreducible anecdote, comparability.
Instead of “my case,” the possibility of a pattern.
It is less innocent than it appears.
Because in standardizing testimony, the platform is not merely organizing information. It is intervening in the conditions under which something can be recognized as knowledge.
It is claiming a place within a hierarchy that has historically separated lived experience from valid evidence — not as a substitute for clinical science, controlled trials, or epidemiological surveillance, but as what these frameworks tend to overlook: the thickness of practice, the time of trial, the silent accumulation of trajectories that do not fit within experimental designs.
What “anecdote” does
Every public controversy generates its own glossary and its own instruments of disqualification. In the debate over tobacco harm reduction, one of them gained particular force: “anecdote.”
Consumers, activists, and pro-THR groups have, for years, heard variations of the same sentence: personal stories are not enough; testimony is not science; individual experiences cannot guide population-level policy.
In strictly methodological terms, the objection is not trivial. Self-reported accounts carry well-known limitations: selection bias, fallible memory, retrospective enthusiasm, lack of controls, and an inability to establish causality with the rigor required by certain research designs.
But “anecdote” does more than point to a technical limitation. It functions as a boundary-making device. It turns a vast body of experience into disposable material. It draws a line, often a comfortable one, between what can circulate as legitimate knowledge and what can be consigned to the sphere of inconsequential subjectivity.
THR Global enters at that boundary. Its most audacious gesture is not to claim that individual testimony is worth more than science, but to suggest that science itself — when translated into policy — may operate incompletely by systematically excluding those who experience the concrete effects of its decisions.
A subtle inversion.
And for that reason, a powerful one.
The question is no longer “are these stories just anecdotes?” It begins to unfold into others. Politically, why do millions of convergent experiences still lack proportional weight in the arenas where health policy is made? Scientifically, why are they still treated as epistemologically invisible, even when, taken together, they begin to delineate a pattern that resists easy dismissal?
What centralization makes possible
Every platform is, first and foremost, a technology of centralization. And every act of centralization — sooner or later — becomes a struggle over power: whoever organizes, defines; whoever defines, hierarchizes; whoever hierarchizes, decides what can circulate as relevant.
In the world of harm reduction, fragmentation among actors, roles, and levels of action has long been a structural weakness.
There are consumer associations in different countries — sometimes more than one within the same territory — as well as support groups, forums, local campaigns, independent studies, and a wide range of narratives scattered across spaces that barely intersect or rarely act in synergy.
Each node operates with what it has at hand, stretching its capacities to cover gaps that more coherent coordination might distribute differently. This disorganization of the symbolic and political division of labor does not stem from individual failure but from the absence of articulation among existing capacities.
The volume is there.
The energy is there as well.
What is often missing is a mechanism to convert dispersed capacities and talents into coordinated action. Without it, collective force tends to fall short of its critical mass.
What is dispersed almost always appears smaller than it really is.
And, in the case, what does not present itself within a shared regime of collection, classification, and presentation tends to seem inconsistent — even when it reflects recurring patterns. This is not merely a question of quantity. It is a question of institutional legibility: the capacity of an experience to be read, compared, retained, and ultimately admitted to the circuits where reality acquires administrative and political consequence.
It is at this point that THR Global intervenes: not in the content of the stories, but in the conditions of their legibility. By centralizing testimonies within a common format, the platform seeks to produce what bureaucracies, reports, and policy frameworks more readily recognize: series, repetition, scale, and archive.
It aims to show that some individuals have managed to quit smoking using less harmful alternatives, and that this outcome recurs across contexts, countries, and conditions, with a consistency that becomes increasingly difficult to ignore.
This is the project’s real ambition: not only visibility but also a more stable form of inscription in the debate — a shared point of reference, an archive that can serve as a resource when those voices are once again reduced to the status of exception, noise, or particular interest.
Questions of credibility
But every platform that sets out to correct a narrative imbalance runs into the same question sooner or later: who authorizes the authorizer?
In the field of tobacco and nicotine, this question is far from rhetorical. Few issues carry such a dense history of corporate fraud, scientific manipulation, aggressive lobbying, and institutional capture. For decades, doubt was manufactured as a survival strategy. That history has not faded; it continues to operate as a lens, a suspicion, a mode of reading.
It is on this mined terrain that THR Global encounters its central paradox.
For its supporters, the project corrects a historical exclusion: it restores presence to consumers systematically marginalized in health debates. For critics — and even for more cautious observers — it occupies a zone of ambiguity, where the language of harm reduction can function as a pathway for the reentry of commercial interests under a new moral and regulatory grammar.
In this context, distrust is not a detail; it is a condition of reading. The platform is not merely competing for attention but for legitimacy. And that contest will be decided less by the sheer volume of testimonies than by how they are produced, organized, scrutinized, and made auditable.
In other words, centralizing stories is not enough. It will be necessary to demonstrate that this centralization functions not merely as a refined technology of persuasion, but as a transparent infrastructure capable of turning lived experience into material that can be examined, compared, and engaged with within public debate.
On the force of biography
Kurt Yeo’s presence in the project’s announcement helps explain why it resonates. He embodies a recurring figure in contemporary harm reduction politics: the long-term smoker who claims to have found, in alternative products, especially flavored vapes, a way out that decades of failed attempts could not provide.
This type of biography — to which, in some way, I also belong — carries a particular force. It strains purism. It displaces the pedagogy of guilt. It suggests that public health does not always prevail when it demands complete and ideal abstinence, and that it may save more lives when it allows for imperfect solutions that are nonetheless less lethal than combustible cigarettes.
The power of this narrative lies in its capacity to speak of failure and survival. Not of theory, but of the body. Not of abstract regulatory design, but of the daily reality of someone who tried to quit and could not — until they did, by a path that many policymakers still hesitate to legitimize.
Yet it is this same biography that exposes a tension difficult to reconcile at the center of the debate. Health authorities view the flavors that, for some adults, were decisive in quitting through a different lens: not as individual experience but as a matter of population-level prevention.
The same product, the same substance — but a regime of evaluation that does not quite know how to handle the concrete success of a smoker when it appears to disrupt the abstract calculus of collective risk. What a personal story describes as redemption may, on the other side, be read as a disturbance to an equilibrium that was never designed to accommodate this kind of evidence.
THR Global situates itself within this contradiction without resolving it.
Perhaps that is not its role. Perhaps its function is different: not to arbitrate between lived success and regulatory concern, but to make the incommensurability between these two regimes more visible and more documented — and harder to dismiss without making explicit which one is being privileged and why.
Perhaps this is the debate’s blind spot: not the absence of data, but the difficulty of allowing distinct forms of evidence to coexist without one negating the other.
Data, and dignity
There is something deeper at stake here than the dispute between clinical studies and what has come to be known as real-world evidence. Platforms like THR Global operate in a zone where information and recognition cease to function as separate spheres. What is at issue is not merely what counts as data, but who is authorized to appear as a subject of knowledge.
For many consumers of lower-risk products, exclusion from the debate does not register merely as a technical error. It is experienced as a form of diminishment: the feeling of not being taken seriously, of not being heard on one’s own terms, of being continually translated into categories that fail to recognize the path one has lived.
This is not only a matter of underrepresentation.
More often, it is the perception of being reduced to an object of policy, never a legitimate interlocutor. In this displacement, something is lost: a form of epistemic dignity. Experience exists, but acquires no status. It speaks, but produces no effect.
This friction produces more than discomfort. It produces a form of revolt — not only against decisions, but against the way certain bureaucracies listen, or fail to listen. There are moments when a voice is recognized only when it confirms the expected script. Outside it, it becomes noise.
This revolt is understandable and, for that reason, vulnerable to capture. It can be mobilized both as a legitimate demand for recognition and as an argument for the dissolution of any form of regulation. The line between autonomy and exposure is not always clear.
THR Global speaks to this discomfort, but does not control it. Its subtext is clear: consumers are not merely recipients of public policy, but producers of knowledge about what worked, what failed, and what remained unresolved in their trajectories.
What the platform offers, therefore, is not merely the collection of data. It is a form of symbolic restitution — an attempt to restore status to experience, not as absolute truth, but as part of a field that has, until now, operated through poorly examined exclusions.
This gesture gains force especially in fields marked by asymmetries of voice, where lived experiences circulate widely but rarely arrive intact at the sites where they acquire institutional weight.
In such environments, gathering testimonies becomes more than an act of documentation. It becomes a form of self-inscription: we were here, we made this transition, our trajectories exist beyond the narrow categories through which they are typically read.
On the limits of the project
But any serious reading must resist the temptation of easy celebration.
First: standardization strengthens, but it also simplifies. Translating life stories into comparable fields entails selection, compression, and variable choice. Part of the density of individual accounts is lost when they are fitted into the model that enables their aggregation. What makes each experience singular — socioeconomic context, regulatory environment, consumer culture, comorbidities, unequal access, family pressures, trajectories of relapse — rarely fits entirely within structured forms.
Second: the classic risk of any advocacy platform — becoming a selective mirror of its most engaged participants. Who submits testimony? Who does not? Who feels compelled to participate — and who remains at the margins? Who has had negative experiences and chooses to remain silent? A collection of this kind can reveal patterns, but the logic of voluntary participation will always shape it.
Third, and most decisive: transforming testimonies into standardized data does not resolve the problem of causality or population-level generalization. A person who quit smoking using vapes may have done so for other reasons — changes in routine, life circumstances, coincidence, or placebo effect. The platform does not control for these variables. It records correlations; it does not establish causation.
This does not invalidate it.
But it imposes a limit and requires humility in how its findings are presented.
The relevance of a platform like THR Global will depend, to a large extent, on its willingness to clearly state what it can and cannot demonstrate. Its political strength lies in the organization of experience, not in any claim to rival, on its own, the best available science.
If it attempts to occupy that position, it weakens itself. If it embraces its specific role — that of a civic infrastructure aimed at making visible a form of evidence often underestimated — it may become harder to ignore. Yet there remains a dissonance that no formulation fully resolves. For those who have lived through this transition — and I include myself — the problem rarely presents itself as a question of method.
It presents itself as a question of time — of repeated attempts, of persistence. It is in this interval that the distance between analysis and experience ceases to be merely theoretical and becomes something far more difficult to sustain.
Where the question shifts
At its core, THR Global is not merely intervening in narratives about vaping or nicotine. It is contesting something more fundamental: the definition of who has the authority to shape what counts as reality.
Global public health organizes itself around aggregated data, meta-analyses, guidelines, conferences, and treaties. Necessarily. But it also rests on silent exclusions: which lives enter the frame as relevant data, and which remain reduced to personal cases without collective consequence.
The platform strains this arrangement by asserting that organized consumer experience can be part of political deliberation — especially in matters involving behavioral transition, risk substitution, and engagement with products that fall outside the classic pharmaceutical model.
The conflict, therefore, is not merely scientific.
It is epistemological and institutional.
THR Global shifts the question: when public policy regulates alternatives to cigarettes, why is the voice of those who have successfully transitioned still denied, or, when it does enter, so late, so weakened, and so often under suspicion? And what would happen if that voice, consistently assembled, began to operate as a pattern rather than an exception?
The answer does not yet exist.
But the question now has infrastructure.
Perhaps the most revealing aspect of THR Global is this: its emergence says as much about the state of the harm reduction movement as it does about the limits of traditional channels of representation. Platforms like this emerge when entire communities come to understand, in practice, that existing instruments were not designed to absorb what they have to say.
THR Global is both a symptom and a strategy.
A symptom of a prolonged impasse between consumers, regulators, researchers, and governments who observe the same phenomenon through distinct moral frameworks and evidentiary models.
A strategy because it attempts to correct this asymmetry not through direct rhetorical confrontation, but through infrastructure: collection, standardization, visibility, scale, memory.
Instead of responding to exclusion with protest alone, it responds with an archive. Instead of reacting to the charge of anecdote with indignation, it responds with method.
A lucid choice. And a risky one.
Lucid because it recognizes that, in the contemporary world, what does not become a system rarely becomes influential.
Risky because any attempt to convert suffering and relief into comparable data runs the risk of being read as advocacy in another guise — or of losing, in the process, part of what gave it force.
In the end, it is difficult not to recognize what is being built.
Calling THR Global a database is accurate, but insufficient.
Calling it an advocacy tool is also accurate, but it’s still not sufficient.
What is emerging is a more ambiguous, counter-chamber of public health policy, where experiences that previously existed in fragments now aim for public consistency.
The premise is clear: that the organized repetition of accounts can generate pressure; that the consumer voice, once made legible, will no longer sound like an exception; that the archive, at times, can do what an isolated argument cannot — sustain presence.
What remains open is how this will be read: as inconvenient evidence to be confronted, or as well-structured advocacy to be neutralized.
For those who know this transition from the inside, that reading is never abstract: it determines whether a lived trajectory is treated as knowledge or returned to the domain of suspicion.
And there is another, quieter risk. In a field marked by deep asymmetries, caution itself can become a vulnerability. Epistemic restraint — necessary to avoid overstating what can be demonstrated — may, on the other side, be read as a lack of force. Between asserting limits and sustaining presence, a difficult interval opens.
Perhaps, for now, THR Global’s most decisive contribution lies not in convincing its critics, but in shifting the terrain of the dispute. In showing that, in the twenty-first century, the struggle for recognition in public health is waged not only in laboratories, guidelines, or treaties, but also in the design of platforms that determine who can be seen, compared, counted, and ultimately considered.
In the global debate on tobacco and nicotine, this may be the most consequential dispute of all. Not because the platform will prevail, but because it has already changed the question.
No longer whether individual stories matter, but how they are assembled into a collective force that counts.
